Lipocine
LPCN
30 hedge funds and large institutions have $3.7M invested in Lipocine in 2018 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 5 closing their positions.
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
16% more capital invested
Capital invested by funds: $3.2M → $3.7M (+$504K)
11% more funds holding
Funds holding: 27 → 30 (+3)
0.21% more ownership
Funds ownership: 0.58% → 0.79% (+0.21%)
36% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 11
57% less call options, than puts
Call options by funds: $16K | Put options by funds: $37K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
+$1M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$91K |
| 3 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$70.1K |
| 4 |
JP Morgan Chase
New York
|
+$54.4K |
| 5 |
VF
Virtu Financial
New York
|
+$35.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MA
MYDA Advisors
Woodmere,
New York
|
-$92K |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$57K |
| 3 |
BlackRock
New York
|
-$55.3K |
| 4 |
Bank of New York Mellon
New York
|
-$37.6K |
| 5 |
QCMA
Quad Capital Management Advisors
New York
|
-$32K |
LPCN Hedge Fund Activity: Q2 2018 in Review
30 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q2 2018, worth a combined $3.7M — up 16% from $3.2M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new LPCN positions and 5 closed out — a net gain of 3 holders — while 7 added to existing stakes and 11 trimmed.
The largest buyer was J. Goldman & Co, opening a new position worth an estimated $1M. The largest seller was MYDA Advisors, exiting entirely with an estimated $92K sold.
- 30 institutional investors held Lipocine (LPCN) as of Q2 2018, up from 27 in Q1 2018.
- Funds reported $3.7M of Lipocine stock for Q2 2018, up 16% quarter-over-quarter.
- 8 funds opened new Lipocine positions in Q2 2018 and 5 closed out, a net change of +3 holders.
- The largest Lipocine buyer in Q2 2018 was J. Goldman & Co, an estimated $1M added.
- The largest Lipocine seller in Q2 2018 was MYDA Advisors, an estimated $92K sold.
Based on aggregated 13F filings for Q2 2018.